Abbott Laboratories (ABT)

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...

ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.

Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their...

Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...

How does getting paid to own a stock sound to you? That's exactly what dividends do.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe...

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.

ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.